Antistreptokinase platelet-activating antibodies are common and heterogeneous

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 5, 2003, Pages 1055-1061

  Regnault, V ^a   Helft, G ^b   Wahl, D ^a,c   Czitrom, D ^b   Vuillemenot, A ^d   Papouin, G ^e   Roda, L ^e   Danchin, N ^c   Lecompte, T ^a,c  

^a INSERM   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e CHT de Mamao ^*  (French Polynesia)

Author keywords

Anti SK antibodies; Coronary artery disease; Platelet activation; Thrombolysis

Indexed keywords

EID: 0346198022     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00210.x     Document Type: Article

References (37)

1. Ohman EM, Harrington RA, Cannon CP, Agnelli G, Cairns JA, Kennedy JW. Intravenous thrombolysis in acute myocardial infarction. Chest 2001; 119: 253S-7S.
2. The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001; 358: 1855-63.
3. Moran DM, Standring R, Lavender EA, Harris GS. Assessment of antistreptokinase antibody levels in human sera using a microradioimmunoassay procedure. Thromb Haemost 1984; 52: 281-7.
4. Declerck PJ, Vanderschueren S, Billiet J, Moreau H, Collen D. Prevalence and induction of circulating antibodies against recombinant staphylokinase. Thromb Haemost 1994; 71: 129-33.
5. Lynch M, Pentecost BL, Littler WA, Stockley RA. The distribution of antibodies to streptokinase. Postgrad Med J 1996; 72: 290-2.
6. Eliott JM, Cross DB, Cederholm-Williams SA, White HD. Neutralizing antibodies to streptokinase four years after intravenous thrombolytic therapy. Am J Cardiol 1993; 71: 640-5.
7. Gemmill JD, Hogg KJ, Dunn FG, Rae AP, Hillis WS. Pre-dosing antibody levels and efficacy of thrombolytic drugs containing streptokinase. Br Heart J 1994; 72: 222-5.
8. Juhlin P, Bostrom PA, Torp A, Bredberg A. Streptokinase antibodies inhibit reperfusion during thrombolytic therapy with streptokinase in acute myocardial infarction. J Intern Med 1999; 245: 483-8.
9. Fears R, Hearn J, Standring R, Anderson JL, Marder VJ. Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction. Am Heart J 1992; 124: 305-14.
10. Shaila G, Chandrashekhar YS, Kumar N, Ganguly NK, Anand IS. Antistreptokinase antibodies before and after streptokinase therapy in patients with acute myocardial infarction from areas endemic for streptococcal infection and influence on reperfusion rates. Am J Cardiol 1994; 74: 187-9.
11. Fitzgerald DJ, Catella F, Roy L, FitzGerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988; 77: 142-50.
12. Vaughan DE, Kirshenbaum JM, Loscalzo J. Streptokinase-induced, antibody-mediated platelet aggregation: a potential cause of clot propagation in vivo. J Am Coll Cardiol 1988; 11: 1343-8.
13. Vaughan DE, Van Houtte E, Declerck PJ, Collen D. Streptokinaseinduced platelet aggregation. Prevalence and mechanism. Circulation 1991; 84: 84-91.
14. Lebrazi J, Helft G, Abdelouahed M, Elalamy I, Mirshahi M, Samama MM, Lecompte T. Human anti-streptokinase antibodies induce platelet aggregation in an Fc receptor (CD32) dependent manner. Thromb Haemost 1995; 74: 938-42.
15. McRedmont JP, Harriott P, Walker B, Fitzgerald DJ. Streptokinaseinduced platelet activation involves antistreptokinase antibodies and cleavage of protease-activated receptor-1. Blood 2000; 95: 1301-8.
16. Heptinstall S, Berridge DC, Judge H. Effects of streptokinase and recombinant tissue plasminogen activator on platelet aggregation in whole blood. Platelets 1990; 1: 177-88.
17. Terres W, Kruger K, Bleifeld W. Prevalence and mechanism of streptokinase-induced platelet stimulation. Effect of acetylsalicylic acid. Eur Heart J 1992; 13: 1514-20.
18. Tcheng JE, Strony J, Lorenz TJ, O'Shea JC. ESPRIT in context: pharmacology matters! Eur Heart J 2001; 22: 1965-7.
19. Warkentin TE, Hayward CPM, Boshkov LK, Santos AV, Sheppard JAI, Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparininduced thrombocytopenia. Blood 1994; 84: 3691-9.
20. Morel MC, Lecompte T, Champeix P, Favier R, Potevin F, Samama M, Salmon C, Kaplan C. PL2-49, a monoclonal antibody against glycoprotein IIb which is a platelet activator. Br J Haematol 1989; 71: 57-63.
21. Lee HS, Yule S, McKenzie A, Cross S, Reid T, Davidson R, Jennings K. Hypersensitivity reactions to streptokinase in patients with high pretreatment antistreptokinase antibody and neutralisation titres. Eur Heart J 1993; 14: 1640-3.
22. Bachelot C, Saffroy R, Gandrille S, Aiach M, Rendu F. Role of FcgRIIA gene polymorphism in human platelet activation by monoclonal antibodies. Thromb Haemost 1995; 74: 1557-63.
23. Warner MN, Pavord S, Moore JC, Warkentin TE, Hayward CP, Kelton JG. Serum-induced platelet procoagulant activity: an assay for the characterization of prothrombotic disorders. J Lab Clin Med 1999; 133: 129-33.
24. Lynch M, Pentecost BL, Littler WA, Stockley RA. The significance of anti-streptokinase antibodies. Clin Exp Immunol 1994; 96: 427-31.
25. Mainet D, del Rosario M, Toruncha A, Prats P, Valenzuela C, Lopez Saura P. Similar, more than 6-months persisted, antibody and neutralizing activity responses in patients with acute myocardial infarction treated with recombinant or natural streptokinase. Fibrinolysis Proteolysis 1998; 12: 301-9.
26. Squire IB, Lawley W, Fletcher S, Holme E, Hillis WS, Hewitt C,Woods KL. Humoral and cellular immune responses up to 7.5 years after administration of streptokinase for acute myocardial infarction. Eur Heart J 1999; 20: 1245-52.
27. Abdelouahed M, Elalamy I, Lebrazi J, Helft G, Mirshahi M, Lecrubier C, Samama MM, Lecompte T. Streptokinase modifies in vitro platelet aggregation by two mechanisms: reduced aggregation due to fibrinogenolysis and enhanced aggregation via an immunological reaction. Platelets 1995; 6: 317-25.
28. Regnault V, Lecompte T, Danchin N, on behalf of the French Clinical Investigators (Besançon, Papeete, Paris). Heterogeneous distribution of the subclass IgG anti-streptokinase antibodies. Fibrinolysis Proteolysis 1998; 12: 53.
29. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79: 1-7.
30. Brandt J, Isenhart CE, Osborne JM, Ahmed A, Anderson CL. On the role of platelet FcγRIIa phenotype in heparin-induced thrombocytopenia. Thromb Haemost 1995; 74: 1564-72.
31. 131) gene in patients with heparin-induced thrombocytopenia. J Lab Clin Med 1997; 130: 278-84.
32. Bachelot-Loza C, Saffroy R, Lasne D, Chatellier G, Aiach M, Rendu F. Importance of the FcγRIIa-Arg/His-131 polymorphism in heparin-induced thrombocytopenia diagnosis. Thromb Haemost 1998; 79: 523-8.
33. Arnaud E, Nicaud V, Poirier O, Rendu F, Alhenc-Gelas M, Fiessinger JN, Emmerich J, Aiach M. Protective effect of a thrombin receptor (protease-activated receptor-1) gene polymorphism toward venous thromboembolism. Arterioscler Thromb Vasc Biol 2000; 20: 585-92.
34. Hemker HC, Giesen PLA, Ramjee M, Wagenvoord R, Béguin S. The thrombogram: monitoring thrombin generation in platelet rich plasma. Thromb Haemost 2000; 83: 589-91.
35. Storey RF, Newby LJ, Heptinstall S. Effects of P2Y1 and P2Y12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 2001; 12: 443-7.
36. ISIS-2 (Second International Study of Infarct Survival) collaborative group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
37. Al Shwafi K, de Meester A, Pirenne B, Col J. Prevalence of streptokinase resistance among acute myocardial infarction patients. Eur Heart J 2000; 21 (Suppl.): 482.